CureVac N.V.

NASDAQ:CVAC   11:56:18 AM EDT
17.56
+0.86 (+5.15%)
Regulatory, Earnings Announcements

Curevac Expects To Start A Phase 1 Clinical Trial Assessing Cv2COV In Q1 Of 2022

Published: 01/07/2022 22:31 GMT
CureVac N.V. (CVAC) - Curevac - Expects to Start a Phase 1 Clinical Trial Assessing Cv2cov in the First Quarter of 2022.
Curevac - Expects to Start Assessing a Modified Second-generation Covid-19 Mrna Vaccine Candidate in a Phase 1 Trial in the Third Quarter of 2022.
Curevac - Estimates That Pivotal Study for Advanced Clinical Development of Covid-19 Vaccine Candidate May Be Initiated in Q4 of 2022.
Curevac - Assessing First Mrna Influenza Vaccine Candidates, Expects to Start Phase 1 Trial With Chemically Non-modified Mrna Candidate in Q1 of 2022.
Curevac - Assessing First Mrna Influenza Vaccine Candidates, Expects to Start Phase 1 Trial With Modified Mrna Candidate in Q3 of 2022.
Curevac - Expects to Publish Data From Its Collaboration With Schepens Eye Research Institute of Mass.
Eye and Ear in H1 of 2022.
Revenue is expected to be $16.13 Million
Adjusted EPS is expected to be -$0.73

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.54

More details on our Analysts Page.